 IV. Evaluating circulating tumor cells CTCs pre- and post- treatment with single agent sunitinib and sunitinib HCQ, and characterize these for markers of autophagy. exploratory V. To determine whether the steady-state plasma concentration of HCQ correlates with inhibition of autophagy and whether a pharmacokinetic interaction exists between sunitinib and HCQ. 